Healthcare provider profile · identity verified

David Cabell Gray, MD

Allopathic & Osteopathic Physicians|Internal Medicine · ALICE, TX · NPI 1902814874

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show David Cabell Gray, MD received $146.14 in general payments during 2025 across 3 reported records.

Baxter Healthcare accounted for 77.8% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 4 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 399 claims for Ozempic by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rybelsus by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$146.14

3 reported records · 3 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Baxter Healthcare	Unresolved — no canonical attribution shown	$113.76	77.8%	1	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$16.47	11.3%	1	2025
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$15.91	10.9%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Long term medical supply or device loan	$113.76	1
Food and Beverage	$32.38	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
Hillrom - Spot Vision Screener Normalized: hillrom spot vision screener	Device	Baxter Healthcare	$113.76	1	2025
Source payment records 2025-08-25 · Baxter Healthcare · $113.76 · Open Payments source
CREON Normalized: creon	Drug	ABBVIE INC.	$16.47	1	2025
Source payment records 2025-11-06 · ABBVIE INC. · $16.47 · Open Payments source
LINZESS Normalized: linzess	Drug	ABBVIE INC.	$16.47	1	2025
Source payment records 2025-11-06 · ABBVIE INC. · $16.47 · Open Payments source
Wegovy Normalized: wegovy	Drug	Novo Nordisk Inc	$15.91	1	2025
Source payment records 2025-02-10 · Novo Nordisk Inc · $15.91 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
LINZESS linzess	2025	Linzess	2024	35 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	LINZESS open payments reported associated product	CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608	Linzess · 2024 Exact normalized brand match · 1 Part D row	35	suppressed by CMS
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	SYNTHROID open payments reported associated product	CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636	Synthroid · 2024 Exact normalized brand match · 1 Part D row	32	suppressed by CMS
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	399	69
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Rybelsus open payments reported associated product	CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076	Rybelsus · 2024 Exact normalized brand match · 1 Part D row	37	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	603	175
Atorvastatin Calcium	Atorvastatin Calcium	565	176
Levothyroxine Sodium	Levothyroxine Sodium	528	127
Losartan Potassium	Losartan Potassium	501	146
Ozempic	Semaglutide	399	69
Gabapentin	Gabapentin	352	95
Rosuvastatin Calcium	Rosuvastatin Calcium	331	110
Metformin Hcl	Metformin Hcl	324	107
Lisinopril	Lisinopril	290	94
Omeprazole	Omeprazole	278	89
Metoprolol Succinate	Metoprolol Succinate	256	72
Carvedilol	Carvedilol	202	62
Tamsulosin Hcl	Tamsulosin Hcl	185	61
Trazodone Hcl	Trazodone Hcl	183	56
Simvastatin	Simvastatin	180	50
Diclofenac Sodium	Diclofenac Sodium	179	64
Hydrochlorothiazide	Hydrochlorothiazide	172	49
Pioglitazone Hcl	Pioglitazone Hcl	166	49
Furosemide	Furosemide	164	59
Jardiance	Empagliflozin	160	37
Pantoprazole Sodium	Pantoprazole Sodium	154	49
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	154	48
Alprazolam	Alprazolam	148	32
Albuterol Sulfate Hfa	Albuterol Sulfate	144	49
Telmisartan	Telmisartan	140	38
Metformin Hcl Er	Metformin Hcl	138	45
Bupropion Xl	Bupropion Hcl	137	38
Zolpidem Tartrate	Zolpidem Tartrate	130	22
Escitalopram Oxalate	Escitalopram Oxalate	127	34
Pravastatin Sodium	Pravastatin Sodium	122	38
Allopurinol	Allopurinol	111	35
Clopidogrel	Clopidogrel Bisulfate	103	32
Metoprolol Tartrate	Metoprolol Tartrate	101	31
Eliquis	Apixaban	100	23
Sertraline Hcl	Sertraline Hcl	99	29
Spironolactone	Spironolactone	91	32
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	90	19
Amitriptyline Hcl	Amitriptyline Hcl	88	29
Ezetimibe	Ezetimibe	85	26
Farxiga	Dapagliflozin Propanediol	85	23
Mirtazapine	Mirtazapine	84	23
Duloxetine Hcl	Duloxetine Hcl	83	26
Montelukast Sodium	Montelukast Sodium	82	22
Hydroxyzine Hcl	Hydroxyzine Hcl	78	23
Xarelto	Rivaroxaban	78	19
Lorazepam	Lorazepam	76	12
Clonazepam	Clonazepam	74	12
Fluticasone Propionate	Fluticasone Propionate	72	27
Methylprednisolone	Methylprednisolone	69	58
Clonidine Hcl	Clonidine Hcl	66	20
Potassium Chloride	Potassium Chloride	66	25
Tresiba Flextouch U-100	Insulin Degludec	66	15
Fluoxetine Hcl	Fluoxetine Hcl	63	19
Mounjaro	Tirzepatide	62	12
Topiramate	Topiramate	56	16
Trulicity	Dulaglutide	56	suppressed
Chlorthalidone	Chlorthalidone	55	17
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	54	15
Triamcinolone Acetonide	Triamcinolone Acetonide	54	34
Hydralazine Hcl	Hydralazine Hcl	53	12
Atenolol	Atenolol	52	14
Tizanidine Hcl	Tizanidine Hcl	52	11
Temazepam	Temazepam	49	suppressed
Alendronate Sodium	Alendronate Sodium	48	17
Benazepril Hcl	Benazepril Hcl	47	16
Famotidine	Famotidine	47	17
Tramadol Hcl	Tramadol Hcl	47	14
Olmesartan Medoxomil	Olmesartan Medoxomil	45	14
Azithromycin	Azithromycin	44	36
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	43	14
Finasteride	Finasteride	43	14
Liothyronine Sodium	Liothyronine Sodium	42	suppressed
Meloxicam	Meloxicam	42	16
Novolog Flexpen	Insulin Aspart	42	12
Oxybutynin Chloride	Oxybutynin Chloride	42	11
Donepezil Hcl	Donepezil Hcl	40	14
Prednisone	Prednisone	40	23
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	39	14
Glipizide Er	Glipizide	37	15
Rybelsus	Semaglutide	37	suppressed
Buspirone Hcl	Buspirone Hcl	36	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	36	32
Citalopram Hbr	Citalopram Hydrobromide	36	suppressed
Linzess	Linaclotide	35	suppressed
Testosterone Cypionate	Testosterone Cypionate	35	suppressed
Paroxetine Hcl	Paroxetine Hcl	34	suppressed
Cefuroxime	Cefuroxime Axetil	32	32
Diazepam	Diazepam	32	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	32	11
Synthroid	Levothyroxine Sodium	32	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	30	suppressed
Eszopiclone	Eszopiclone	28	suppressed
Irbesartan	Irbesartan	28	suppressed
Valsartan	Valsartan	28	suppressed
Vascepa	Icosapent Ethyl	28	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	26	18
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	26	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	26	suppressed
Myrbetriq	Mirabegron	26	suppressed
Methocarbamol	Methocarbamol	25	suppressed
Ondansetron Hcl	Ondansetron Hcl	25	suppressed
Propranolol Hcl	Propranolol Hcl	25	suppressed
Symbicort	Budesonide/Formoterol Fumarate	25	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	24	suppressed
Estradiol	Estradiol	24	suppressed
Promethazine Hcl	Promethazine Hcl	24	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	24	suppressed
Ipratropium Bromide	Ipratropium Bromide	22	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	22	suppressed
Celecoxib	Celecoxib	21	11
Eplerenone	Eplerenone	21	suppressed
Nifedipine Er	Nifedipine	21	suppressed
Glimepiride	Glimepiride	20	suppressed
Ondansetron Odt	Ondansetron	20	suppressed
Ropinirole Hcl	Ropinirole Hcl	20	suppressed
Ventolin Hfa	Albuterol Sulfate	20	suppressed
Letrozole	Letrozole	19	suppressed
Lovastatin	Lovastatin	19	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	19	suppressed
Nebivolol Hcl	Nebivolol Hcl	19	suppressed
Azelastine Hcl	Azelastine Hcl	18	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	18	suppressed
Valacyclovir	Valacyclovir Hcl	18	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	18	suppressed
Aripiprazole	Aripiprazole	17	suppressed
Cholestyramine	Cholestyramine (With Sugar)	17	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	17	14
Lamotrigine	Lamotrigine	17	suppressed
Nexletol	Bempedoic Acid	17	suppressed
Ramipril	Ramipril	17	suppressed
Terazosin Hcl	Terazosin Hcl	17	suppressed
Torsemide	Torsemide	17	suppressed
Ciclopirox	Ciclopirox Olamine	16	14
Fluconazole	Fluconazole	16	11
Glipizide	Glipizide	16	suppressed
Levemir Flexpen	Insulin Detemir	16	suppressed
Raloxifene Hcl	Raloxifene Hcl	16	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	16	suppressed
Lactulose	Lactulose	15	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	15	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	15	12
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	15	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	15	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	14	suppressed
Meclizine Hcl	Meclizine Hcl	14	11
Naproxen	Naproxen	14	suppressed
Pregabalin	Pregabalin	14	suppressed
Testosterone	Testosterone	14	suppressed
Advair Diskus	Fluticasone Propion/Salmeterol	13	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	13	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	13	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	13	suppressed
Glycopyrrolate	Glycopyrrolate	13	suppressed
Humalog Kwikpen U-100	Insulin Lispro	13	suppressed
Larin Fe	Norethindrone-E.Estradiol-Iron	13	suppressed
Memantine Hcl	Memantine Hcl	13	suppressed
Mupirocin	Mupirocin	13	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	13	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	13	suppressed
Propranolol Hcl Er	Propranolol Hcl	13	suppressed
Terbinafine Hcl	Terbinafine Hcl	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	11
Doxazosin Mesylate	Doxazosin Mesylate	12	suppressed
Levetiracetam	Levetiracetam	12	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	12	suppressed
Breyna	Budesonide/Formoterol Fumarate	11	suppressed
Crestor	Rosuvastatin Calcium	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Ibuprofen	Ibuprofen	11	suppressed
Levofloxacin	Levofloxacin	11	suppressed
Primidone	Primidone	11	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$146.14 · 3 records	Baxter Healthcare	CREON, Hillrom - Spot Vision Screener, LINZESS, Wegovy	4	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Linzess play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error